AIGR Deep Research Report: MBL2 and Surfactant Homeostasis (GO:0043129)

Gene: MBL2 (mannose-binding lectin 2) · Organism: Homo sapiens (NCBITaxon:9606) · UniProt: P11226 (Mannose-binding protein C) Focus type: function_assignment · Hypothesis slug: function-hypothesis-go-0043129 Seed hypothesis: MBL2 has surfactant homeostasis (GO:0043129). Annotation under review: GO:0043129 "surfactant homeostasis", evidence IBA (ECO:0000318), reference GO_REF:0000033

Summary

The proposed function assignment — that MBL2 directly participates in surfactant homeostasis (GO:0043129) — is over-annotated and refuted as a direct function of MBL2. On MBL2 (P11226) the term exists only as an IBA (phylogenetic) annotation from GO_REF:0000033, with zero experimental support (no IDA, IMP, IPI, or IGI) anywhere in MBL2's ~94 GO annotations. The annotation is best explained as a paralog carry-over propagated across the collectin family tree from the true pulmonary surfactant collectins, SP-D (SFTPD) and SP-A (SFTPA1/2).

The biology of MBL2 is inconsistent with an alveolar surfactant role. MBL2 is a liver-synthesized, secreted serum collectin whose experimentally characterized function is initiation of the lectin pathway of complement — Ca²⁺-dependent recognition of microbial carbohydrate arrays, MASP protease activation, and downstream opsonization/phagocytosis. UniProt annotates it as "secreted" and "produced mainly in the liver," with no alveolar/lung localization and no surfactant lipid- or protein-handling activity. Surfactant homeostasis, by contrast, is an alveolar process executed by SP-A/SP-D, the lamellar-body lipid transporter ABCA3, and surfactant-processing proteases (CTSH, NAPSA) — genes that carry GO:0043129 with genuine experimental (IDA/IMP/ISS) support.

The one structural fact that both explains the mis-annotation and cautions the curator is that MBL2 and SP-D are close collectin paralogs — both built from an N-terminal collagen-like region plus a C-type lectin carbohydrate-recognition domain (CRD), with ~56% full-length identity and ~50% CRD identity. This kinship is exactly what allows a phylogenetic annotation pipeline to project a lung-branch function onto a serum-branch member. The similarity is real; the functional inference is not. Recommended curation lead (requires curator verification): remove or down-rank GO:0043129 on MBL2 as a non-core, low-confidence IBA carry-over, retaining the term on SFTPD/SFTPA where it is experimentally supported.

Key Findings

Finding F001 — GO:0043129 on MBL2 is an unsupported IBA paralog carry-over from SP-D

The single confirmed finding of this investigation is that MBL2's surfactant-homeostasis annotation has no gene-specific experimental basis and is a computational inheritance from its surfactant-collectin paralogs. The evidence has four interlocking parts.

1. Evidence provenance: the term is IBA-only. In the QuickGO annotation record for MBL2 (P11226), GO:0043129 is carried solely as IBA (ECO:0000318, GO_REF:0000033). Across MBL2's full complement of ~94 GO annotations there is no experimental evidence code attached to the surfactant term. IBA ("Inferred from Biological Ancestor") is produced by the GO Phylogenetic Annotation (PAINT/PAN-GO) project: a curator annotates ancestral nodes of a gene tree, and the annotation is propagated to descendant genes. It is a prediction based on family membership, and by GO convention it is explicitly non-experimental. IBA is a procedurally valid evidence code — it is not "wrong" as a mechanism — but here it represents biological over-reach.

2. Where the experimental support actually lives. Of the 16 human genes annotated to GO:0043129, experimental support is concentrated in genes with direct, measured surfactant biology, whereas MBL2 sits in an IBA-only tier alongside an adhesion GPCR and a pseudogene:

The company MBL2 keeps in the IBA-only tier is itself a red flag: genuine surfactant biology comes with experimental annotations; MBL2's does not.

3. Structural paralogy drives the carry-over. MBL2 is a collectin — signal peptide (1–20), an N-terminal cysteine-rich/collagen-like region (~42–99), a coiled-coil neck (~112–130), and a C-terminal C-type lectin CRD (~134–245). SP-D (SFTPD) shares this exact modular architecture. Pairwise Needleman–Wunsch alignment gives full-length identity of 56.1% and CRD identity of ~50% between MBL2 and SFTPD (for comparison, MBL2–SFTPA1 ~35% and SFTPD–SFTPA1 ~51%). In a gene-family tree, MBL2 and SFTPD sit close together, so any term annotated to a surfactant-collectin ancestor can be projected onto MBL2 by IBA even though MBL2 never acquired surfactant function.

4. MBL2 biology contradicts an alveolar/surfactant role. UniProt (P11226) describes MBL2 as secreted and a "plasma protein produced mainly in the liver." Its annotated and experimentally supported function is a Ca²⁺-dependent lectin that initiates the lectin pathway of complement — binding mannose/GlcNAc on microbial surfaces, oligomerizing into higher-order "bouquets," complexing with MASP proteases, and driving opsonization and phagocytosis. MBL2's experimentally supported GO terms include GO:0001867 (complement activation, lectin pathway; IDA 9087411), pattern-recognition-receptor activity, mannose binding (GO:0005537), and antibacterial defense. There is no UniProt localization to lung, alveolar type II cells, or the surfactant lining layer, and no annotated participation in surfactant lipid/protein turnover.

Interpretation. GO:0043129 on MBL2 reflects family-level inference, not gene-level function. The term is legitimately experimental on SP-D/SP-A and legitimately propagates within the pulmonary-collectin subfamily, but MBL2 is a serum complement collectin in a different compartment performing a different process. The annotation is therefore an over-annotation on MBL2.

Mechanistic Model / Interpretation

The crux of this case is distinguishing shared architecture from shared function. Collectins are a family defined by a collagen-like stalk plus a C-type lectin CRD, but different collectins are deployed in different anatomical compartments for different biological jobs.

                         COLLECTIN FAMILY (collagen region + C-type lectin CRD)
                                          |
        ------------------------------------------------------------------------
        |                                 |                                     |
   SERUM / COMPLEMENT                 PULMONARY / SURFACTANT             OTHER (CL-L1, CL-K1...)
        |                                 |
     MBL2 (P11226)                  SFTPD (SP-D), SFTPA1/2 (SP-A)
   liver-derived, secreted          alveolar type II / Clara cells
        |                                 |
   Ca2+-dependent binding to         Ca2+-dependent binding to surfactant
   microbial sugar arrays            lipids/proteins + pathogens
        |                                 |
   MASP-1/2/3 complexes              regulate surfactant pool size,
   -> lectin complement pathway       structure, and reuptake
   -> opsonization / phagocytosis    -> SURFACTANT HOMEOSTASIS (GO:0043129)
        |                                 |
   [INNATE IMMUNITY core]            [SURFACTANT HOMEOSTASIS core]
        |
        └── GO:0043129 attaches to MBL2 ONLY by IBA (phylogenetic carry-over),
            NOT by any experimental measurement of MBL2.

Both branches share a Ca²⁺-dependent CRD and a collagen stalk, so a phylogenetic annotation pipeline readily projects a term from the pulmonary branch onto the serum branch. But the compartment (serum vs. alveolus), the cellular source (hepatocyte vs. alveolar type II/Clara cell), and the downstream effector system (MASP/complement vs. surfactant lipid turnover) all differ. Surfactant homeostasis is a property of the SP-D/SP-A branch; its appearance on MBL2 is a false positive of family-level inference.

A useful mental test for the curator: Would loss of MBL2 perturb alveolar surfactant pool size or composition? The published MBL2 loss-of-function literature centers on infection susceptibility, complement activity, and immune modulation — not on pulmonary surfactant metabolism, and not on alveolar proteinosis (the SP-D knockout phenotype). MBL2 shares the molecular tool (a Ca²⁺-dependent CRD) but not the biological process.

Evidence Base

The evidence matrix below summarizes the most decision-relevant items. A striking pattern emerges: every experimentally grounded description of MBL2 function points to the lectin complement pathway and innate immunity, and none describes MBL2 participating in surfactant metabolism. The experimental home of GO:0043129 is SP-D, not MBL2.

Evidence Matrix

How the literature bears on the hypothesis

Across the retrieved primary literature, every experimentally grounded description of MBL2 function points to the lectin complement pathway and innate immunity — carbohydrate recognition, MASP association, opsonization, phagocytosis, and infection/disease susceptibility (PMID:15060079, PMID:21091907, PMID:16410008, PMID:18952132). None describes MBL2 participating in alveolar surfactant metabolism. Family reviews (PMID:22475410) and CL-L1 work (PMID:23814060) reinforce that collectins share architecture but are compartmentalized into distinct functional niches — the structural basis for why an IBA pipeline mis-assigns the surfactant term to MBL2. The experimental home of GO:0043129 is SP-D (PMID:19265061, PMID:9751757), not MBL2.

GO Curation Implications

Term: GO:0043129 "surfactant homeostasis" (Biological Process). Current action on MBL2: annotated, IBA (ECO:0000318), GO_REF:0000033.

Recommended curation action (lead — requires curator verification):

• Remove or down-rank GO:0043129 on MBL2 as a non-core, over-annotated term. It is IBA-only, conflicts with MBL2's liver/serum localization, and its experimental basis in the family resides in the SP-A/SP-D lung branch. If retained for procedural completeness, explicitly flag it as a low-confidence phylogenetic carry-over that does not represent MBL2's biology.
• Retain GO:0043129 on the genuine surfactant genes where it is experimentally supported — SFTPD (IDA/IMP), plus BPIFA1, CTSH/NAPSA, ABCA3.
• Elevate MBL2's experimentally supported terms as its core annotations:
• BP: complement activation, lectin pathway (GO:0001867, IDA 9087411); innate immune / antimicrobial signaling; defense response to Gram-positive bacterium (GO:0050830).
• MF: mannose binding (GO:0005537); pattern recognition receptor activity (GO:0038187); Ca²⁺-dependent protein binding (GO:0048306).
• CC: extracellular region / secreted (GO:0005576). Note that MBL2's IBA-only CC term GO:0005771 (multivesicular body) also warrants curator scrutiny.
• Do not default to "protein binding" (GO:0005515); the specific mannose-binding-lectin / lectin-complement-pathway terms are supported and preferable.

MF / BP / CC judgment: GO:0043129 is a BP term. The evidence does not support this BP for MBL2. It supports a different BP (lectin complement pathway) plus specific MF/CC terms. The surfactant BP should be removed/generalized-away on MBL2, not retained as core.

Mechanistic Scope

The immediate molecular activity under interrogation is whether MBL2's Ca²⁺-dependent C-type lectin CRD participates in surfactant homeostasis — regulation of the pool size, composition, or turnover of pulmonary surfactant lipids/proteins in the alveolar lining layer.

• Direct gene-product activity of MBL2: Ca²⁺-dependent binding of terminal mannose/GlcNAc on microbial glycan arrays (CRD, ~134–245); oligomerization via the N-terminal collagen-like region (~42–99) and coiled-coil neck (~112–130) into higher-order bouquets; formation of complexes with MASP-1/2/3; triggering of the lectin complement pathway (C4/C2 cleavage) → opsonization and phagocytosis. This is the measured function.
• Surfactant homeostasis (the tested term): a distinct alveolar process executed by SP-A/SP-D (surfactant collectins), ABCA3 (lamellar-body lipid transport), and surfactant-processing proteases (CTSH, NAPSA). MBL2 has no measured activity in this process, no alveolar type-II-cell expression, and no lamellar-body role.
• Downstream/pleiotropic effects of MBL2 loss (increased infection susceptibility, altered dendritic-cell cytokines, disease associations) are immune phenotypes, not pulmonary surfactant phenotypes — they do not support GO:0043129.

The distinction matters because IBA can conflate a shared molecular tool (a Ca²⁺-dependent CRD) with a shared biological process (surfactant homeostasis). MBL2 shares the tool but not the process.

Conflicts and Alternatives

1. Paralog confusion (the dominant alternative, and the likely truth). MBL2 and SP-D/SP-A are close collectin paralogs (~56% full-length identity, ~50% CRD identity). The surfactant term legitimately belongs to the pulmonary collectin branch and is projected onto MBL2 by phylogenetic inference. This is the parsimonious explanation for the IBA annotation.
2. Compartment mismatch. MBL2 is serum/liver-derived; surfactant homeostasis is alveolar. No primary literature places MBL2 in the alveolar lining fluid as a surfactant regulator.
3. Database carry-over. GO_REF:0000033 is the standard reference for GO phylogenetic (IBA) annotations, confirming the term's origin is the PAN-GO/PAINT pipeline rather than a curated experimental paper.
4. Competing core function. MBL2's experimentally supported role — lectin complement pathway / innate immunity (PMID:9087411, PMID:15060079) — is a strong, well-documented alternative that should anchor the review.
5. No isoform or artifact rescue. MBL2 has a single characterized secreted product; there is no lung-expressed isoform performing surfactant functions. The discrepancy is evolutionary annotation carry-over, not an isoform-specific role.

No retrieved evidence conflicts with the refutation; all alternatives point the same way (family carry-over, not a real MBL2 surfactant function).

Limitations and Knowledge Gaps

• Database snapshot dependency. The finding rests on the current QuickGO/GO annotation state (evidence codes, GO_REF). A curator should re-verify that GO:0043129 on MBL2 remains IBA-only at review time.
• Negative-evidence caveat. Absence of an experimental annotation is not proof of absence of function. What was checked: MBL2 GO provenance, the GO:0043129 gene set, UniProt localization/function, and paralogy. The gap: no direct experimental assay was found testing MBL2 for surfactant-lipid binding or alveolar surfactant turnover. Why it matters: the crux is IBA-only status; a targeted negative experiment (e.g., MBL2 CRD vs. DPPC binding) would formally close it. Resolver: a deep literature search for "mannose-binding lectin AND pulmonary surfactant / DPPC / alveolar" — none surfaced in the immunity-focused searches performed.
• Ancestral-node question. Whether the PAN-GO/PANTHER ancestral node annotation should itself be re-curated (which would also affect ADGRF5 and BPIFA4P IBA) is unresolved; resolver is a PAN-GO tree review.
• Provenance re-verification. The SFTPD experimental references (19265061 IDA; 9751757 IMP) and MBL2's 9087411 lectin-pathway support were taken from the annotation graph; their exact snippets should be pulled and confirmed before citation.
• Alignment parameters. The reported identities (56.1% full-length, ~50% CRD) came from pairwise NW alignment of MBL2 vs. SFTPD; a curator should confirm the exact isoform and parameters used.
• Non-human mechanistic data. Some CRD-specificity detail derives from rat MBP-A/MBP-C (PMID:10589993); human specifics may differ, though the compartmentalization principle holds.

Discriminating Tests

To decisively separate "MBL2 has surfactant homeostasis" from "MBL2 is a serum complement lectin mis-annotated by paralogy":

1. Expression/localization check. Query GTEx/Human Protein Atlas: confirm MBL2 mRNA/protein is liver-restricted with negligible alveolar type-II-cell expression, while SP-D is lung-dominant. (Programmatic, decisive.)
2. Annotation provenance audit. Confirm via QuickGO API that GO:0043129 on P11226 is ECO:0000318 (IBA)/GO_REF:0000033 with no IDA/IMP/IPI. (Directly resolves the curation question.)
3. Binding assay. Test MBL2 CRD for DPPC/surfactant-lipid binding vs. SP-D positive control (predict negative/nonspecific).
4. Knockout phenotype comparison. MBL2-deficient humans/mice show infection susceptibility, not alveolar proteinosis/surfactant accumulation (contrast with SP-D KO). Any surfactant phenotype would be discriminating.
5. PAN-GO tree audit. Inspect where in the collectin tree GO:0043129 was placed and whether the serum-collectin subclade should be pruned.

Proposed Follow-up Experiments / Actions

For the curator (immediate, low-cost): - Re-pull the QuickGO annotation for P11226 and confirm GO:0043129 is IBA-only; if so, flag for removal/down-ranking on MBL2. - Verify that the SFTPD references (19265061, 9751757) support GO:0043129 on SFTPD, and retain the term there. - Retrieve 9087411 and extract the exact snippet documenting MBL2's lectin-pathway experimental annotation before using it as MBL2's core BP support. - Also scrutinize MBL2's other IBA-only terms — GO:0005771 (multivesicular body, CC) and GO:0050766 (positive regulation of phagocytosis, the latter biologically plausible via opsonization and possibly upgradeable to experimental).

Computational provenance to run/record: - MBL2 vs. SFTPD global and CRD-only NW alignment, saving the alignment and percent-identity table. - MBL2 tissue-expression pull (GTEx/HPA), saving the expression table showing liver dominance. - PANTHER/PAINT node inspection to document the ancestral origin of the IBA propagation.

Curation Leads (require curator verification):

Conclusion

The seed hypothesis that MBL2 has surfactant homeostasis (GO:0043129) is over-annotated / refuted as a direct function. The annotation is an IBA (phylogenetic) paralog carry-over with zero MBL2-specific experimental support, propagated from the true pulmonary surfactant collectins SP-D/SP-A across a structurally similar but functionally distinct family. MBL2's experimentally established role is initiating the lectin pathway of complement as a liver-derived, secreted serum lectin in innate immunity. The recommended lead is to remove or down-rank GO:0043129 on MBL2 while retaining it on the genuine surfactant genes, and to anchor the MBL2 review on its complement/innate-immunity core functions.